Immunity Impact Factor 2025

IMMUNOLOGY REVOLUTIONHow Immunity Shaped the Modern Immunotherapy Era

The past fifteen years have witnessed the most dramatic expansion of immunology into clinical practice since the advent of vaccination. Checkpoint inhibitors, CAR-T cell therapies, and monoclonal antibody platforms have moved from benchside curiosity to frontline oncology treatment. At the center of this revolution, Immunity has functioned as the primary scientific witness, publishing the mechanistic studies that underpinned these therapeutic breakthroughs.

When James Allison’s work on CTLA-4 blockade and Tasuku Honjo’s PD-1 research matured into clinical reality, the mechanistic details, tumor microenvironment studies, and resistance-factor analyses that explained why these therapies worked were published in journals like Immunity. The journal’s emphasis on rigorous mechanistic immunology made it the natural venue for studies dissecting T-cell exhaustion, neoantigen recognition, and the immunological synapse, all of which proved essential to engineering better therapeutics.

Similarly, the CAR-T cell revolution depended on a deep understanding of T-cell signaling, cytokine release, and target antigen selection. Many of the foundational papers mapping these pathways, particularly those characterizing CD19-directed CAR constructs and their associated toxicities, appeared in Immunity before clinical translation. This pattern, where the journal publishes the basic science that enables clinical translation within 3-5 years, has become a hallmark of its editorial vision.

JCR 2025 DATAImpact Factor, Quartile, and Bibliometric Position

According to the Clarivate Journal Citation Reports 2025 edition, Immunity holds an Impact Factor of 32.5, maintaining its position in the first quartile (Q1) of the Immunology category. The journal is indexed in SCIE (Science Citation Index Expanded) and is published monthly by Cell Press, an imprint of Elsevier.

With an H-Index of approximately 420, Immunity has accumulated one of the highest citation footprints in the immunology discipline. This metric indicates that 420 distinct papers published in the journal have each received at least 420 citations, a threshold that reflects both the volume and longevity of its most influential contributions. The CiteScore of 37.2 and SJR of 8.41 confirm strong performance across Scopus-derived metrics as well.

LANDMARK PAPERSImmunology Breakthroughs Published in Immunity

What distinguishes Immunity from general-interest journals is the concentration of field-defining papers within its pages. While Nature and Science publish immunology papers of broad interest, Immunity has been the destination for studies that immunologists themselves consider canonical. Several categories of breakthrough have appeared with particular frequency:

T-cell biology and exhaustion. The characterization of T-cell exhaustion states, the epigenetic remodeling that accompanies chronic antigen exposure, and the reversibility of exhaustion through checkpoint blockade all built upon studies published in Immunity. The journal’s willingness to publish large-scale mechanistic studies, often involving extensive in vivo mouse work and human sample validation, made it the venue of choice for laboratories decoding these processes.

Innate immune memory and trained immunity. The paradigm shift from viewing innate immunity as a static, non-adaptive system to recognizing trained immunity, epigenetic reprogramming in monocytes and macrophages, and the long-term consequences of inflammatory exposure was substantially documented in Immunity. Mihai Netea’s work on trained immunity and the broader field of innate lymphoid cell biology found early and sustained support from the journal’s editorial board.

Tumor microenvironment dissection. As checkpoint inhibitors moved into clinical practice, understanding the tumor immune microenvironment, including myeloid-derived suppressor cells, regulatory T-cell infiltration, and the spatial organization of immune infiltrates, became essential. Immunity published many of the single-cell transcriptomic atlases and spatial profiling studies that now form the reference maps for tumor immunology.

Autoimmunity and tolerance. From regulatory T-cell biology to the mechanisms of central and peripheral tolerance, Immunity has maintained a strong commitment to autoimmunity research. Studies on AIRE-dependent thymic selection, IL-2 signaling in Treg maintenance, and the genetic architecture of autoimmune diseases have all appeared in its pages.

TREND ANALYSISHistorical Impact Factor Trajectory

Immunity was launched in 1994 as Cell Press’s specialized immunology title, filling a gap between the broad-scope Cell journal and the growing volume of immunology research that required a dedicated venue. Its early years established a pattern of publishing highly selective, mechanistically rigorous papers that quickly earned the journal a reputation for quality over quantity.

The Impact Factor trajectory reflects this positioning. In the early 2000s, the journal’s IF ranged between 15 and 20, already placing it among the top immunology venues. The most dramatic increase occurred between 2014 and 2020, when the immunotherapy revolution drove unprecedented citation attention to mechanistic immunology papers. During this period, Immunity‘s Impact Factor climbed from the low-20s to above 30, peaking in the 2022-2023 reporting cycle before stabilizing in the low-30s range.

The 2025 value of 32.5 represents a slight moderation from peak levels, consistent with broader trends in immunology publishing where the initial surge of checkpoint-blockade citations has normalized while new fields, such as microbiome-immunity interactions and AI-driven immune engineering, have begun contributing fresh citation volume. The journal’s ability to maintain an IF above 30 through this transition demonstrates editorial adaptability and continued relevance to the field’s cutting edge.

SCOPE & FOCUSWhat Immunity Publishes and Why It Matters

Immunity publishes research across the full spectrum of immunological investigation, with particular strength in areas where mechanistic depth connects to biological or therapeutic significance. The journal’s scope encompasses:

• Lymphocyte biology: T-cell development, activation, differentiation, exhaustion, and memory; B-cell biology, antibody responses, and germinal center dynamics.
• Innate immunity: Macrophage and dendritic cell biology, innate lymphoid cells, NK cell function, inflammasome biology, and pattern recognition receptor signaling.
• Tumor immunology: Cancer immunosurveillance, tumor immune evasion, immunotherapy mechanisms, adoptive cell therapy, and tumor microenvironment biology.
• Autoimmunity and tolerance: Regulatory T-cell biology, mechanisms of self-tolerance, autoimmune disease pathogenesis, and immune checkpoint biology in non-malignant contexts.
• Infection and inflammation: Host-pathogen interactions, vaccine responses, cytokine biology, and inflammatory disease mechanisms.
• Systems and computational immunology: Single-cell transcriptomics, immune repertoire analysis, and AI-driven immune prediction models.

The editorial preference leans toward studies that provide mechanistic insight rather than purely descriptive findings. A paper reporting a novel immune subset is more likely to succeed if it includes functional characterization, in vivo relevance, and a clear path to biological significance. This editorial philosophy has kept the journal’s content tightly connected to the field’s most pressing questions.

PUBLISHER CONTEXTCell Press and the Immunology Portfolio

Immunity is published by Cell Press, the Cambridge, Massachusetts-based scientific publishing imprint acquired by Elsevier in 1998. Cell Press operates with substantial editorial independence, maintaining its own in-house editorial staff who are practicing scientists with direct research experience. This model, distinct from the editor-in-chief model at many society journals, allows Cell Press titles to make rapid, informed decisions on technically complex manuscripts.

Within the Cell Press portfolio, Immunity occupies a specialized niche alongside broader titles like Cell and clinical-focused journals like Cancer Cell and Cell Stem Cell. The journal benefits from the Cell Press production infrastructure, including professional editorial staff, rapid online publication, and integration with Elsevier’s ScienceDirect platform. Authors publishing in Immunity gain access to Cell Press’s media relations support, which has proven effective at amplifying the visibility of high-impact papers.

The Cell Press brand carries significant weight in immunology. The “Cell family” journals are widely perceived as maintaining rigorous peer review standards, and affiliation with the imprint signals editorial selectivity. For researchers in immunology, a publication in Immunity represents both scientific achievement and entry into a recognized publishing ecosystem that spans from basic molecular immunology to clinical trials.

FIELD COMPARISONHow Immunity Compares to Leading Immunology Journals

Immunology publishing is concentrated among a small number of high-impact journals, each with distinct editorial personalities. Immunity competes most directly with Nature Immunology, while Journal of Experimental Medicine and Journal of Immunology serve complementary but partially overlapping niches.

The comparison with Nature Immunology is particularly instructive. Both journals pursue top-tier mechanistic immunology and frequently compete for the same manuscripts. Immunity‘s higher Impact Factor (32.5 vs. 28.8) reflects, in part, its stronger representation in the tumor immunology space, where citation velocity has been highest over the past decade. Nature Immunology maintains broader coverage across immunological subdisciplines, including more content in transplant immunology and allergy, fields with lower average citation rates.

Journal of Experimental Medicine, founded in 1896 and published by Rockefeller University Press, offers a longer publication history and retains particular strength in autoimmunity and vascular immunology. Its lower Impact Factor (17.1) reflects a more inclusive acceptance policy and a tradition of publishing comprehensive, multi-year studies that accumulate citations over longer periods rather than generating immediate citation spikes.

Journal of Immunology, the official journal of the American Association of Immunologists, serves as the field’s broad-access society journal. Its Impact Factor of 5.2 places it in a different tier, but it publishes substantially more papers and maintains deep connections to the practicing immunology community. For authors choosing between these venues, the decision often comes down to a trade-off between selectivity and reach.

FAQFrequently Asked Questions About Publishing in Immunology